Lilly's drug, abemaciclib, is from the same new class of breast
cancer treatments as Pfizer Inc's recently approved drug, Ibrance.
In August, Lilly elected to continue the late-stage study, even
though an interim look at the data suggested the combination
treatment was not delaying disease progression.
The trial compared combined use of Lilly's abemaciclib and
anti-estrogen therapy fulvestrant with fulvestrant alone, the
drugmaker said on Monday.
Lilly is evaluating abemaciclib as a single agent in breast cancer
patients who have not derived enough benefit from prior treatments,
and multiple other studies are testing abemaciclib with other drugs.
Abemaciclib, which was granted U.S. Food and Drug Administration
breakthrough therapy status for breast cancer in 2015, is also being
tested for use in lung cancer.
[to top of second column]
Lilly said it planned to submit an application to market abemaciclib
as a monotherapy in the second quarter, and as a combination therapy
in the third quarter.
(Reporting by Natalie Grover in Bengaluru; Editing by Sai Sachin
Ravikumar and Martina D'Couto)
[© 2017 Thomson Reuters. All rights
Copyright 2017 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.